Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | FPR2 | P25090 | 1/20 | 0.55 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.53 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4315790 | 1.00 | HRH4 (0.65) | HRH4KMT2AMEN1MAPTFPR2 | |
| SCHEMBL4338439 | 1.00 | HRH4 (0.65) | HRH4KMT2AMEN1MAPTFPR2 | |
| SCHEMBL4315976 | 0.87 | AKR1C3 (0.65) | HRH4KMT2AMEN1AKR1C3 | |
| SCHEMBL4315799 | 0.87 | AKR1C3 (0.65) | HRH4KMT2AMEN1AKR1C3 | |
| SCHEMBL4324486 | 0.87 | AKR1C3 (0.65) | HRH4KMT2AMEN1AKR1C3 | |
| SCHEMBL4324550 | 0.86 | HRH4 (0.68) | HRH4KMT2AMEN1FPR2 | |
| SCHEMBL4324552 | 0.86 | HRH4 (0.68) | HRH4KMT2AMEN1FPR2 | |
| SCHEMBL4327646 | 0.86 | HRH4 (0.68) | HRH4KMT2AMEN1FPR2 | |
| SCHEMBL25531368 | 0.86 | HRH4 (0.62) | HRH4KMT2AMEN1FPR2AKR1C3 | |
| SCHEMBL30375295 | 0.85 | HRH4 (0.55) | HRH4KMT2AMEN1MAPTFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101472584-B | Indoles and benzoimidazoles as histamine H4 receptor modulators | JANSSEN PHARMACEUTICA NV | 2013-04-24 | — | — | CN | claimed |
| EP-2010172-B1 | INDOLES AND BENZOIMIDAZOLES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-29 | — | — | EP | claimed |
| CN-101472584-A | Indoles and benzoimidazoles as histamine H4 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-01 | — | — | CN | claimed |
| US-7544698-B2 | Indoles and benzoimidazoles as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-09 | — | — | US | claimed |
| EP-2010172-A2 | INDOLES AND BENZOIMIDAZOLES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007117401-A2 | INDOLES AND BENZOIMIDAZOLES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-18 | — | — | WO | claimed |
| US-20070238771-A1 | Indoles and benzoimidazoles as histamine H4 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-11 | — | — | US | claimed |
| EP-2010172-B1 | INDOLES AND BENZOIMIDAZOLES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-29 | — | — | EP | disclosed |
| EP-2010172-B1 | INDOLES AND BENZOIMIDAZOLES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-29 | — | — | EP | disclosed |
| US-7544698-B2 | Indoles and benzoimidazoles as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-09 | — | — | US | disclosed |
| US-7544698-B2 | Indoles and benzoimidazoles as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-09 | — | — | US | disclosed |
| US-20070238771-A1 | Indoles and benzoimidazoles as histamine H4 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238771-A1 | Indoles and benzoimidazoles as histamine H4 receptor modulators | HRH4, HRH3, HRH1 | HRH4 1/4885KMT2A 538/4885MEN1 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.